Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
InflaRx N.V. (IFRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IFRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -30.07% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 67.80M USD | Price to earnings Ratio - | 1Y Target Price 9.3 |
Price to earnings Ratio - | 1Y Target Price 9.3 | ||
Volume (30-day avg) 394271 | Beta 2.22 | 52 Weeks Range 0.97 - 2.81 | Updated Date 04/4/2025 |
52 Weeks Range 0.97 - 2.81 | Updated Date 04/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 2308149.2% |
Management Effectiveness
Return on Assets (TTM) -33.77% | Return on Equity (TTM) -56.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14754708 | Price to Sales(TTM) 408.98 |
Enterprise Value 14754708 | Price to Sales(TTM) 408.98 | ||
Enterprise Value to Revenue 81.61 | Enterprise Value to EBITDA 0.5 | Shares Outstanding 67133296 | Shares Floating 50522550 |
Shares Outstanding 67133296 | Shares Floating 50522550 | ||
Percent Insiders 6.44 | Percent Institutions 19.51 |
Analyst Ratings
Rating 4.4 | Target Price 7.97 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
InflaRx N.V.
Company Overview
History and Background
InflaRx N.V. is a biopharmaceutical company focused on discovering and developing novel anti-inflammatory therapeutics. It was founded in 2007 and is headquartered in Jena, Germany. The company has focused primarily on developing inhibitors targeting the complement system, particularly C5a.
Core Business Areas
- Drug Development: Research, development, and commercialization of biopharmaceuticals targeting inflammatory diseases.
- Complement System Inhibition: Focus on therapies that inhibit the complement system, specifically the C5a protein.
Leadership and Structure
The leadership team consists of experienced professionals in the pharmaceutical industry. The company's structure includes research and development, clinical operations, and commercialization teams.
Top Products and Market Share
Key Offerings
- Vilobelimab: Vilobelimab is a novel monoclonal anti-C5a antibody. The drug is used to reduce the C5a activity during inflammatory diseases. Vilobelimab has shown promising results and is in clinical development stage. Currently, there are no approved therapeutic alternatives addressing C5a inhibition specifically, the main competitors are companies working in broad anti-inflammatory medication such as Roche (RHHBY).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. InflaRx N.V. operates within the segment focused on inflammatory diseases and complement system modulation.
Positioning
InflaRx N.V. is positioned as a company specializing in complement system inhibition, offering a novel approach to treating inflammatory conditions. Its competitive advantage lies in its specific targeting of C5a.
Total Addressable Market (TAM)
The TAM for complement-targeted therapies is substantial, estimated in billions of dollars. InflaRx N.V. is positioned to capture a portion of this market with its vilobelimab program.
Upturn SWOT Analysis
Strengths
- Novel C5a inhibitor
- Strong intellectual property
- Experienced management team
Weaknesses
- Limited product portfolio
- Dependence on clinical trial success
- High cash burn rate
Opportunities
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
- Growing market for complement-targeted therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Funding Risks
Competitors and Market Share
Key Competitors
- ALNY
- CRSP
- VCYT
- AMGN
- BMY
Competitive Landscape
InflaRx N.V. faces competition from larger, more established pharmaceutical companies with broader product portfolios and greater financial resources. Its competitive advantage is its specific C5a inhibition focus.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: InflaRx's growth has been dependent on its clinical development programs and financial backing.
Future Projections: Future growth is heavily dependent on the success of vilobelimab and other pipeline assets. Analyst estimates vary based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing vilobelimab through clinical trials for various indications, securing funding for ongoing research and development.
Summary
InflaRx N.V. is a clinical-stage biopharmaceutical company specializing in complement system inhibition, particularly targeting C5a. Its future prospects rely heavily on the success of its vilobelimab program and the potential to expand into new indications. The company faces significant risks related to clinical trials, competition, and funding. A major strength is its novel therapeutic approach and experienced leadership, but weaknesses include a limited product portfolio and reliance on clinical trial successes.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
AMGN
Amgen Inc
AMGN
Amgen Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
VCYT
Veracyte Inc
VCYT
Veracyte Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InflaRx N.V.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-11-08 | Co-Founder, CEO & Executive Director Dr. Niels C. Riedemann M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.inflarx.de |
Full time employees 74 | Website https://www.inflarx.de | ||
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.